| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U |
| P698 | PubMed publication ID | 10898341 |
| P2093 | author name string | Hiraga T | |
| Michigami T | |||
| Niewolna M | |||
| Williams PJ | |||
| Yi B | |||
| Yoneda T | |||
| P2860 | cites work | TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development | Q33834762 |
| Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure | Q34216753 | ||
| Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro | Q34793691 | ||
| The clinical course of bone metastases from breast cancer | Q36027636 | ||
| Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action | Q36466679 | ||
| Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. | Q37367672 | ||
| Osteolytic bone metastasis in breast cancer | Q40568075 | ||
| Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. | Q41087450 | ||
| Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review | Q41723658 | ||
| Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. | Q42543174 | ||
| Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group | Q44160812 | ||
| In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates | Q46151864 | ||
| A novel orthotopic model of breast cancer metastasis to bone. | Q52826484 | ||
| Uracil-tegafur in gastric carcinoma: a comprehensive review. | Q55067761 | ||
| Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 | ||
| P433 | issue | 12 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 2979-2988 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma | |
| P478 | volume | 88 |
| Q73245873 | A novel rodent mammary window of orthotopic breast cancer for intravital microscopy |
| Q33941303 | A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites |
| Q24802119 | Actions of bisphosphonates in animal models of breast cancer |
| Q36491357 | Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? |
| Q38007855 | Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated? |
| Q37321938 | Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up |
| Q53635529 | Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour. |
| Q53489280 | Animal Models of Bone Metastasis. |
| Q38848170 | Anti-Resorptive Functions of Poly(ethylene sodium phosphate) on Human Osteoclasts. |
| Q53911491 | Bisphosphonate Induced Growth Inhibition of Breast Cancer Cells is Augmented by p38 Inhibition |
| Q40268466 | Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells |
| Q44057163 | Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts |
| Q42616085 | Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia |
| Q34293923 | Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models |
| Q43797851 | Comparative physicochemical properties and cytotoxicity of polyphosphoester ionomers with bisphosphonates. |
| Q34111208 | Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Position Emission Tomography Imaging Agent |
| Q36491529 | Does estrogen play a role in response to adjuvant bone-targeted therapies? |
| Q28473783 | Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models |
| Q40106076 | Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats |
| Q36942524 | Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant |
| Q58577597 | Enoxacin and bis-enoxacin stimulate 4T1 murine breast cancer cells to release extracellular vesicles that inhibit osteoclastogenesis |
| Q33925506 | Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer |
| Q34825844 | Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo |
| Q42132237 | HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition |
| Q37078073 | High-resolution in vivo imaging of fluorescent proteins using window chamber models. |
| Q33785586 | Histone/protein deacetylase SIRT1 is an anticancer therapeutic target |
| Q31034846 | Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. |
| Q36451429 | Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer |
| Q33358981 | Imagable 4T1 model for the study of late stage breast cancer |
| Q35053318 | In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis |
| Q93070784 | In vivo characteristics of human and mouse breast tumor cell lines |
| Q50620041 | Inhibition of osteolytic bone metastasis by unfractionated heparin. |
| Q39105402 | Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma |
| Q39352902 | Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo |
| Q57456604 | Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival |
| Q48255383 | MDA-MB-435 human breast carcinoma metastasis to bone |
| Q54508468 | Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies. |
| Q48315762 | Modeling and integral X-ray, optical, and MRI visualization of multiorgan metastases of orthotopic 4T1 breast carcinoma in BALB/c mice |
| Q36375023 | Models of bone metastasis |
| Q35227499 | Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer |
| Q33958925 | Molecular mechanisms of cancer pain |
| Q39426582 | Mono- and Combined Therapy of Metastasizing Breast Carcinoma 4T1 with Zoledronic Acid and Doxorubicin |
| Q78424029 | Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma |
| Q34553964 | Mouse models of breast cancer metastasis |
| Q41682777 | Murine model of hepatic breast cancer |
| Q45068305 | Nano-pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases |
| Q55001510 | Nanopulse Stimulation (NPS) Induces Tumor Ablation and Immunity in Orthotopic 4T1 Mouse Breast Cancer: A Review. |
| Q37146402 | Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. |
| Q47404613 | Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model |
| Q41346254 | Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation |
| Q37336471 | Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. |
| Q33715937 | Platelet and osteoclast β 3 integrins are critical for bone metastasis |
| Q38174455 | Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. |
| Q38901380 | Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen. |
| Q28242046 | Relevance of breast cancer cell lines as models for breast tumours: an update |
| Q33961949 | S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer |
| Q46402734 | Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. |
| Q24802817 | Should all adjuvant breast cancer patients receive a bisphosphonate? |
| Q36695888 | Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells |
| Q27654559 | Structural Basis for Antibody Discrimination between Two Hormones That Recognize the Parathyroid Hormone Receptor |
| Q35169027 | TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells |
| Q35019664 | The anti-tumour activity of bisphosphonates. |
| Q36644394 | The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells |
| Q28362972 | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
| Q36462328 | The complexities of TGF-β action during mammary and squamous cell carcinogenesis |
| Q44157915 | The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs |
| Q53621774 | The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. |
| Q35550375 | The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia |
| Q33688792 | The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm |
| Q46904792 | Turning ecology and evolution against cancer |
| Q30416231 | Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine |
| Q26785501 | Use of Animal Models in Understanding Cancer-induced Bone Pain |
| Q33705995 | Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. |
| Q34122791 | Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma |
| Q37387512 | alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion |
| Q30661731 | rDrak1, a novel kinase related to apoptosis, is strongly expressed in active osteoclasts and induces apoptosis |
Search more.